Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

COPENHAGEN, Denmark, July 1, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces several key executive management changes to optimize value from its proprietary AI-Immunology™ platform and pipeline.

Read more at globenewswire.com